# A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

> **NCT04615273** · PHASE3 · COMPLETED · sponsor: **Ascendis Pharma Endocrinology Division A/S** · enrollment: 264 (actual)

## Conditions studied

- Growth Hormone Deficiency
- Endocrine System Diseases
- Hormone Deficiency

## Interventions

- **DRUG:** Lonapegsomatropin
- **OTHER:** Placebo
- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT04615273
- **Lead sponsor:** Ascendis Pharma Endocrinology Division A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-03
- **Primary completion:** 2023-11-02
- **Final completion:** 2023-12-01
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615273, "A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04615273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*